Metabolic syndrome and other cardiovascular risk factors associated with the progression of IgA nephropathy

Clinical Kidney Journal

Volumn 6, Issue 4, 2013, Pages 395-401

  Kovács, Tibor ^a   Vas, Tibor ^a   Kovesdy, Csaba P ^b   Késõi, István ^a   Sági, Balázs ^a   Wittmann, István ^a   Nagy, Judit ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

cardiovascular risk factors; chronic kidney disease progression; end stage renal disease; IgA nephropathy; metabolic syndrome

Indexed keywords

CREATININE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERURICEMIA; IMMUNOGLOBULIN A NEPHROPATHY; KAPLAN MEIER METHOD; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SMOKING;

EID: 84881461716     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfs131     Document Type: Article

References (45)

1. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497
2. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716
3. Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004; 140: 167-174
4. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005; 16: 2134-2140
5. Schena FP, Pesce F. Epidemiology and ancestral difference. In: Lai KN (ed). Recent Advances in IgA Nephropathy. New Jersey: World Scientific Publishing Co., 2009, pp. 9-20
6. Berthoux CB, Mohey H. Clinical course of primary IgA nephropathy. In: Lai KN (ed). Recent Advances in IgA Nephropathy. New Jersey: World Scientific Publishing Co., 2009, pp. 107-120
7. Floege J, Feehally J. IgA nephropathy: recent developments. J Am Soc Nephrol 2000; 11: 2395-2403
8. Barrat J, Feehally J. IgA nephropathy. J Am Soc Nephrol 2005; 16: 2088-2097
9. Bonett F, Deplere C, Sassolas A et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kid Dis 2001; 37: 720-727
10. Syrjänen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000; 15: 34-42
11. Yamamoto R, Nagasawa Y, Shoji T et al. Cigarette smoking and progression of IgA nephropathy. Am J Kidney Dis 2010; 56: 313-324
12. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005; 112: 2735-2752
13. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
14. Thadhani R, Tonelli M. Cohort studies: marching forward. Clin J Am Soc Nephrol 2006; 1: 1117-1123
15. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106: 286-292
16. Lastra G, Manrique C, McFarlane S et al. Cardiometabolic syndrome and chronic kidney disease. Curr Diab Rep 2006; 6: 207-212
17. Natali A, Pucci G, Boldrini B et al. Metabolic syndrome: at the crossroads of cardiorenal risk. J Nephrol 2009; 22: 29-38
18. Zoccali C. Overweight, obesity and metabolic alterations in chronic kidney disease. Contributions Soc Biol Med Sci MASA 2009; 30: 17-31
19. Locatelli F, Pozzoni P, Del Vecchio L. Renal manifestations in the metabolic syndrome. J Am Soc Nephrol 2006; 17: S81-S85
20. Ritz E. Metabolic syndrome and kidney disease. Blood Purif 2008; 26: 59-62
21. Mallamaci F, Leonardis D, Tripepi G. The metabolic syndrome and chronic kidney disease epidemics: severing the link. Port J Nephrol Hypert 2007; 21: 71-76
22. Thomas G, Sehgal AR, Kashyap SR et al. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2011; 6: 2364-2373
23. Lucove J, Vupputuri S, Heiss G et al. Metabolic syndrome and the development of CKD in American Indians: the Strong Heart Study. Am J Kidney Dis 2008; 51: 21-28
24. Tanaka H, Shiohira Y, Uezu Y et al. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int 2006; 69: 369-374
25. Rashidi A, Ghanbarian A, Azizi F. Are patients who have metabolic syndrome without diabetes at risk for developing chronic kidney disease? Evidence based on data from a large cohort screening population. Clin J Am Soc Nephrol 2007; 2: 976-983
26. Chen J, Gu D, Chen C-S et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant 2007; 22: 1100-1106
27. Lea J, Cheek D, Thornley-Brown D et al. Metabolic syndrome, proteinuria, and the risk of progressive CKD in hypertensive African Americans. Am J Kidney Dis 2008; 51: 732-740
28. Luk AO, So WY, Ma RC et al. Metabolic syndrome predicts new onset of chronic kidney disease in 5,829 patients with type 2 diabetes: a 5-year prospective analysis of the Hong Kong Diabetes Registry. Diabetes Care 2008; 31: 2357-2361
29. Jang SY, Kim IH, Ju EY et al. Chronic kidney disease and metabolic syndrome in a general Korean population: the Third Korea National Health and Nutrition Examination Survey (KNHANES III) Study. J Public Health 2010; 32: 538-546
30. Zhang LX, Zuo L, Wang F et al. Metabolic syndrome and chronic kidney disease in a Chinese population aged 40 years and older. Mayo Clin Proc 2007; 82: 822-827
31. Yang T, Chu CH, Hsu CH et al. Impact of metabolic syndrome on the incidence of chronic kidney disease: a Chinese cohort study. Nephrology 2012; 17: 532-538
32. Sun F, Tao Q, Zhan S. Metabolic syndrome and the development of chronic kidney disease among 118 924 non-diabetic Taiwanese in a retrospective cohort. Nephrology 2010; 15: 84-92
33. Lee CC, Sun CY, Wu IW et al. Metabolic syndrome loses its predictive power in late-stage chronic kidney disease progression - a paradoxical phenomenon. Clin Nephrol 2011; 75: 141-149
34. Fliser D, Pacini G, Engelleiter R et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998; 53: 1343-1347
35. Nagy J, Kovacs T. Special clinical syndromes. In: Lai KN (ed). Recent Advances in IgA Nephropathy. New Jersey: World Scientific Publishing Co., 2009, pp. 121-138
36. Kövesdy CP, Trivedi BK, Kalantar-Zadeh K et al. Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease. Nephrol Dial Transplant 2006; 21: 1257-1262
37. Nagy J, Kovács T, Wittmann I. Renal protection in IgA nephropathy requires strict blood pressure control. Nephrol Dial Transplant 2005; 20: 1533-1539
38. Kwan BCH, Murtaugh MA, Beddhu S. Associations of body size with metabolic syndrome and mortality in moderate chronic kidney disease. Clin J Am Nephrol 2007; 2: 992-998
39. Kopple JD, Feroze U. The effect of obesity on chronic kidney disease. J Ren Nutr 2011; 21: 66-71
40. Hsu C-Y, McCulloch CE, Iribarren C et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144: 21-28
41. Madero M, Sarnak MJ, Wang Y et al. Body mass index and mortality in CKD. Am J Kidney Dis 2007; 3: 404-411
42. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Paradoxical association between body mass index and mortality in men with CKD not yet on dialysis. Am J Kid Dis 2007; 49: 581-591
43. Tanaka M, Yamada S, Iwasaki Y et al. Impact of obesity on IgA nephropathy: comparative ultrastructural study between obese and non-obese patients. Nephron Clin Pract 2009; 112: 71-78
44. Muntner J, Coresh J, Smith J et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in community study. Kidney Int 2000; 58: 293-301
45. Fried F, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a metaanalysis. Kidney Int 2001; 59: 260-269